Alliqua BioMedical, Inc. (NASDAQ:ALQA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
| Entry into a Material Definitive Agreement. |
The information set forth in Item 8.01 of this Current Report on
Form 8-K is incorporated herein by reference.
| Item 5.08 | Shareholder Director Nominations. |
On April 26, 2017, the Board of Directors of Alliqua BioMedical,
Inc. (the Company) established June 23, 2017, as the date for the
Companys 2017 Annual Meeting of Stockholders (the Annual Meeting)
and set April 28, 2017, as the record date for the Annual
Meeting. Due to the fact that the date of the Annual Meeting has
been changed by more than 30 days from the anniversary date of
the 2016 Annual Meeting of Stockholders, the Company is providing
the due date for submission of any qualified stockholder proposal
or qualified stockholder nominations.
In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the
Securities Exchange Act of 1934, as amended (the Exchange Act),
and the Companys bylaws, the deadline for receipt of stockholder
proposals or nominations for inclusion in the Companys proxy
statement for the Annual Meeting to Rule 14a-8 will be no later
than 12:00 p.m., Eastern Time, May 8, 2017. Stockholder proposals
must comply with all of the applicable requirements set forth in
the rules and regulations of the Securities and Exchange
Commission, including Rule 14a-8 under the Exchange Act and the
Companys bylaws.
| Item 8.01 | Other Events. |
As previously reported, on March 13, 2017, the Company and each
of Celgene Corporation (Celgene), and Jerome Zeldis, M.D., Ph.D.,
entered into a side letter, to which, among other things, the
Company agreed to use its reasonable best efforts to solicit
stockholder approval for certain issuances of shares of the
Companys common stock to Celgene and Dr. Zeldis, as set forth in
the respective side letter, at an annual or special meeting of
stockholders of the Company to be promptly called and held prior
to May 31, 2017 (the Stockholder Meeting Deadline).
On April 26, 2017, the Company and each of Celgene and Dr. Zeldis
agreed to extend the Stockholder Meeting Deadline to July 31,
2017.
About Alliqua BioMedical, Inc. (NASDAQ:ALQA)
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal. Alliqua BioMedical, Inc. (NASDAQ:ALQA) Recent Trading Information
Alliqua BioMedical, Inc. (NASDAQ:ALQA) closed its last trading session up +0.013 at 0.428 with 90,948 shares trading hands.
